Full Press Release Details
TriSalus Life Sciences Provides Updates on
Pressure-Enabled Regional Immuno-Oncology (PERIO ) 01 and 02 Clinical Studies
and CHICAGO, November 21, 2022 - TriSalus Life Sciences , Inc. ("TriSalus") (the "Company"),
an oncology therapeutics company in the process of going public through a business combination transaction (the "Business Combination")
with MedTech Acquisition Corporation (Nasdaq: MTAC) ("MedTech" or "MTAC"), today filed a presentation for investors
with additional information regarding its ongoing Pressure-Enabled Regional Immuno-Oncology ("PERIO 01")
and ("PERIO 02") clinical studies for primary and metastatic liver tumors.
"We are commercializing our TriNav Infusion System (TriNav )
and developing SD-101 to potentially enable more patients with liver and pancreatic tumors to benefit from immunotherapeutics and the
current standard of care," said Mary Szela, President and Chief Executive Officer of TriSalus. "Today we are providing recent
clinical data from our SD-101 studies so investors can better understand the progress to date and the potential upside that our company
"The initial findings from these studies offer encouraging data
supporting TriSalus' proprietary Pressure-Enabled Drug Delivery ("PEDD ") method," said Steven C.
Katz, MD, FACS, Chief Medical Officer at TriSalus. "This promising clinical data demonstrate that SD-101 delivered via TriNav
may support broad immune effects in liver tumors and eliminate myeloid-derived suppressor cells ("MDSC"). Importantly, the
data further substantiates the potential of our therapeutic platform to significantly improve immunotherapy outcomes for patients with
liver and pancreatic tumors."
Highlights of the presentation include:
The full presentation has been filed with the Securities and Exchange
Commission ("SEC") and is accessible on TriSalus' investor relations page at https://trisaluslifesci.com/investors/.
About TriSalus and Its Proposed Business Combination with MedTech
TriSalus is an oncology therapeutics company integrating immunotherapy
with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors.
TriSalus' proprietary platform approach addresses immune dysfunction
in liver and pancreatic tumors by combining its highly effective drug delivery technology with immunotherapeutics. The TriSalus platform
comprises the TriNav Infusion System and SD-101, a class C toll-like receptor 9 (TLR9) agonist. TriNav is an FDA-cleared device
that is designed to administer established and emerging therapeutics. SD-101, the Company's investigational TLR9 agonist, is being
delivered via TriNav to selected sites, including tumors in the liver. TriNav is the latest TriSalus asset for the proprietary
PEDD method of administration which has been shown to overcome intra-tumoral pressure through modulation of pressure and flow to
increase delivery of therapeutic agents.
As previously announced on November 14, 2022, TriSalus has entered
into a definitive merger agreement with MedTech (the "Merger Agreement"), a publicly traded special purpose acquisition company
in connection with the proposed business combination and related transactions between the parties. Upon the closing of the transaction,
which is expected to occur in the first quarter of 2023, the combined company will be a publicly traded company and its common stock is
expected to be listed on the NASDAQ Stock Exchange under the ticker "TLSI". The transaction is subject to the satisfaction
of the necessary regulatory approvals and customary closing conditions, including the approval of MedTech's shareholders.
To learn more about the clinical trial treatment protocol and enrollment,
visit http://www.periotrial.com or http://www.clinicaltrials.gov and search NCT04935229, NCT05220722, NCT05607953.
About MedTech Acquisition Corporation
MedTech is a blank check company formed for
the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with
one or more businesses or entities. MedTech has stated a focus on the medical technology industry in the United States and other developed
Forward-Looking Statements
This communication contains certain "forward-looking
statements" within the meaning of the United States federal securities laws regarding MTAC's or TriSalus's expectations,
hopes, beliefs, assumptions, intentions or strategies regarding the future including, without limitation, statements regarding: (i) the
tolerability of SD-101 infusion with TriNav, (ii) the potential of TriSalus's proprietary PEDD method to enable SD-101 to
have broad immune effects in liver tumors and eliminate MDSC, (iii) expectations for continuing program development and potential outcomes,
(iv) TriSalus's ability to compete with other companies, and (v) expectations for topline data and regulatory approval. These forward-looking
statements generally are identified by words such as "anticipate," "believe," continue," "could,"
"estimate," "expect," "intend," "may," "might," "plan," "possible,"
"potential," "predict," "project," "should," "strive," "would,"
"will" and similar expressions or the negative or other variations of such statements. These statements are predictions, projections
and other statements about future events that are based on various assumptions, whether or not identified in this communication and on
the current expectations of MTAC's and TriSalus's respective managements and are not predictions of actual performance and,
as a result, are subject to risks and uncertainties.
Many factors could cause actual results
or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to:
(i) the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of
MTAC's securities; (ii) the risk that the Business Combination may not be completed by MTAC's business combination deadline
and the potential failure to obtain an extension of the business combination deadline; (iii) the failure to satisfy the conditions to
the consummation of the Business Combination, including the approval of the Merger Agreement by the stockholders of MTAC, the satisfaction
of the minimum cash amount following any redemptions by MTAC's public stockholders, and the receipt of certain governmental and
regulatory approvals, including reimbursement approval; (iv) the lack of a third-party valuation in determining whether or not to pursue
the Business Combination; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the
Merger Agreement; (vi) the receipt of an unsolicited offer from another party for an alternative transaction that could interfere with
the Business Combination, (vii) the effect of the announcement or pendency of the Business Combination on TriSalus's business relationships,
operating results and business generally; (viii) risks that the Business Combination disrupts current plans and operations of TriSalus;
(ix) the outcome of any legal proceedings that may be instituted against TriSalus or MTAC related to the Merger Agreement or the Business
Combination; (x) the ability to maintain the listing of MTAC's securities on the Nasdaq; (xi) changes in business, market, financial,
political and legal conditions; (xii) unfavorable changes in the reimbursement environment for TriSalus's products; (xiii) TriSalus's
product candidates not achieving success in preclinical or clinical trials or not being able to obtain regulatory approval, either on
a timely basis or at all or subject to any conditions that negatively impact TriSalus's ability to commercialize the applicable
product candidates; (xiv) TriSalus being unable to continue to grow TriNav sales; (xv) the size of the addressable markets for TriNav
and TriSalus's product candidates, if successfully developed and approved by the applicable regulatory authorities, being less than
TriSalus estimates; (xvi) TriSalus's ability to successfully commercialize any product candidates that it successfully develops
and that are approved by applicable regulatory authorities; (xvii) TriSalus's ability to continue to fund preclinical and clinical
trials for its product candidates; (xviii) TriSalus's ability to partner with other companies; (xix) future economic and market
conditions; the development, effects and enforcement of laws and regulations affecting TriSalus's business or industry; (xx) TriSalus's
ability to manage future growth; (xxi) TriSalus's ability to maintain and grow its market share; (xxii) the effects of competition
on TriSalus's business; (xxiii) the ability of MTAC or the combined company to raise additional financing in connection with the
Business Combination or to finance its operations in the future; (xxiv) the ability to implement business plans, forecasts and other expectations
after the completion of the Business Combination, and identify and realize additional opportunities; (xxv) costs related to the Business
Combination; and (xxvi) the failure to realize the anticipated benefits of the Business Combination or to realize estimated pro forma
results and the underlying assumptions, including with respect to estimated stockholder redemptions. The foregoing list of factors is
You should carefully consider the foregoing
factors and other risks and uncertainties described in the "Risk Factors" section of MTAC's Annual Report on Form 10-K
for the fiscal year ended December 31, 2021, filed with the SEC on March 2, 2022 (the "2021 Form 10-K"), the preliminary
proxy statement/prospectus on Form S-4 relating to the Business Combination, which is expected to be filed by MTAC with the SEC and other
documents filed by MTAC from time to time with the SEC. These filings identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and
none of MTAC, TriSalus, or any of their respective representatives assume any obligation and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events, or otherwise. None of MTAC, TriSalus, or any of their respective representatives
gives any assurance that either MTAC or TriSalus will achieve its expectations.
Changes and Additional Information in Connection with SEC Filing
The information in this communication has not been reviewed by the
SEC and certain information may not comply in certain respects with SEC rules. MTAC intends to file a registration statement on Form S-4
(the "Registration Statement") that will include a proxy statement/prospectus of MTAC, that will be both the proxy
statement to be distributed to holders of MTAC's common stock in connection with its solicitation of proxies for the vote by MTAC's